Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death
Open Access
- 23 September 2002
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 87 (7), 805-812
- https://doi.org/10.1038/sj.bjc.6600547
Abstract
Nutrient deprivation has been shown to cause cancer cell death. To exploit nutrient deprivation as anti-cancer therapy, we investigated the effects of the anti-metabolite 2-deoxy-D-glucose on breast cancer cells in vitro. This compound has been shown to inhibit glucose metabolism. Treatment of human breast cancer cell lines with 2-deoxy-D-glucose results in cessation of cell growth in a dose dependent manner. Cell viability as measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide conversion assay and clonogenic survival are decreased with 2-deoxy-D-glucose treatment indicating that 2-deoxy-D-glucose causes breast cancer cell death. The cell death induced by 2-deoxy-D-glucose was found to be due to apoptosis as demonstrated by induction of caspase 3 activity and cleavage of poly (ADP-ribose) polymerase. Breast cancer cells treated with 2-deoxy-D-glucose express higher levels of Glut1 transporter protein as measured by Western blot analysis and have increased glucose uptake compared to non-treated breast cancer cells. From these results we conclude that 2-deoxy-D-glucose treatment causes death in human breast cancer cell lines by the activation of the apoptotic pathway. Our data suggest that breast cancer cells treated with 2-deoxy-D-glucose accelerate their own demise by initially expressing high levels of glucose transporter protein, which allows increased uptake of 2-deoxy-D-glucose, and subsequent induction of cell death. These data support the targeting of glucose metabolism as a site for chemotherapeutic intervention by agents such as 2-deoxy-D-glucose.Keywords
This publication has 74 references indexed in Scilit:
- Glucose Deprivation Does Not Affect GLUT1 Targeting in 3T3-L1 AdipocytesBiochemical and Biophysical Research Communications, 2000
- Reassessment of FDG uptake in tumor cells: High FDG uptake as a reflection of oxygen-independent glycolysis dominant energy productionNuclear Medicine and Biology, 1997
- Hypoglycemia-induced c-Jun Phosphorylation Is Mediated by c-Jun N-terminal Kinase 1 and Lyn Kinase in Drug-resistant Human Breast Carcinoma MCF-7/ADR CellsPublished by Elsevier ,1997
- The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor modelsNuclear Medicine and Biology, 1996
- Improving cancer radiotherapy with 2-deoxy-d-glucose: phase I/II clinical trials on human cerebral gliomasInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Functional Organization of Mammalian Hexokinase IIJournal of Biological Chemistry, 1996
- Hexokinase receptors: Preferential enzyme binding in normal cells to nonmitochondrial sites and in transformed cells to mitochondrial sitesJournal of Bioenergetics and Biomembranes, 1992
- Over-expression of facilitative glucose transporter genes in human cancerBiochemical and Biophysical Research Communications, 1990
- Information from combined 1H and 31P NMR studies of cell extracts: Differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cellsBiochemical and Biophysical Research Communications, 1990
- On the Origin of Cancer CellsScience, 1956